- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Video
Highlighting the Molluscum Contagiosum Pipeline
Author(s):
In this video, Peter Lio, MD, FAAD, expands on his presentation at the 19th annual Winter Clinical Dermatology Conference by diving into molluscum contagiousum treatment and the potential of cantharidin 0.7% (VP-102; Verrica).
Peter Lio, MD, FAAD, clinical assistant professor of dermatology and pediatrics at Northwestern University Feinberg School of Medicine in Chicago, Illinois; founding director of the Chicago Integrative Eczema Center; and founding partner of Medical Dermatology Associates of Chicago, gave a presentation called, "What's Hot and New in Pediatric Dermatology," at the 19th annual Winter Clinical Dermatology Conference. In this video he goes into deep detail on current treatment, cantharidin 0.7% (VP-102; Verrica) potential FDA approval, and more.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
